Lista de obras -

Adult Refsum disease: a form of tapetoretinal dystrophy accessible to therapy

artículo científico publicado en 2010

Alpha‐oxidation of 3‐methyl‐substituted fatty acids and its thiamine dependence ⬇️

artículo científico publicado el 1 de abril de 2003

Are products with an orphan designation for oncology indications different from products for other rare indications? A retrospective analysis of European orphan designations granted between 2002-2012

artículo científico publicado en 2017

Breakdown of 2-hydroxylated straight chain fatty acids via peroxisomal 2-hydroxyphytanoyl-CoA lyase: a revised pathway for the alpha-oxidation of straight chain fatty acids

artículo científico publicado en 2005

Call for a dedicated European legal framework for bacteriophage therapy.

artículo científico publicado en 2014

Causes of drug shortages in the legal pharmaceutical framework

artículo científico publicado en 2015

Clinical, Economic and Policy Implications of Drug Shortages in the European Union.

artículo científico publicado en 2016

Development and implementation of "Check of Medication Appropriateness" (CMA): advanced pharmacotherapy-related clinical rules to support medication surveillance

artículo científico publicado en 2019

Drug shortages in European countries: a trade-off between market attractiveness and cost containment?

artículo científico publicado en 2014

Evaluation of drotrecogin alpha use in a Belgian university hospital

artículo científico publicado en 2006

Financial based agreements and performance based agreements: the Belgian experience.

artículo científico publicado en 2015

Further studies on the substrate spectrum of phytanoyl-CoA hydroxylase: implications for Refsum disease?

artículo científico publicado en 2003

High-risk medication in community care: a scoping review

artículo científico publicado en 2020

Industry Perspectives on Market Access of Innovative Drugs: The Relevance for Oncology Drugs

artículo científico publicado en 2016

Insights into European drug shortages: a survey of hospital pharmacists

artículo científico publicado en 2015

It is time to revise the international Good Clinical Practices guidelines: recommendations from non-commercial North-South collaborative trials

artículo científico publicado en 2016

Managed Entry Agreements for Oncology Drugs: Lessons from the European Experience to Inform the Future

artículo científico publicado en 2017

Market access of cancer drugs in European countries: improving resource allocation

artículo científico publicado en 2013

Meropenem -valproic acid interaction in patients with cefepime-associated status epilepticus.

artículo científico publicado en 2007

Optimizing the European regulatory framework for sustainable bacteriophage therapy in human medicine

artículo científico

Osteoporosis after combined use of a neuroleptic and antidepressants

artículo científico publicado en 2008

Paving a regulatory pathway for phage therapy. Europe should muster the resources to financially, technically and legally support the introduction of phage therapy.

artículo científico publicado en 2013

Predictors for reimbursement of oncology drugs in Belgium between 2002 and 2013.

artículo científico publicado en 2015

Presence of thiamine pyrophosphate in mammalian peroxisomes

artículo científico publicado en 2007

Role of thiamine pyrophosphate in oligomerisation, functioning and import of peroxisomal 2-hydroxyacyl-CoA lyase

artículo científico publicado en 2011

Sharing of Clinical Trial Data and Samples: The Cancer Patient Perspective

artículo científico publicado en 2020

Sponsorship in non-commercial clinical trials: definitions, challenges and the role of Good Clinical Practices guidelines

artículo científico publicado en 2015

Tamoxifen metabolism and efficacy in breast cancer- a prospective multicentre trial

artículo científico publicado en 2018

The necessity for a European definition of drug shortages

scientific article published on 01 August 2018

Thiamine pyrophosphate: an essential cofactor in the mammalian metabolism of 3-methyl-branched fatty acids--implications for thiamine deficiencies?

artículo científico publicado en 2003

Time Investment in Drug Supply Problems by Flemish Community Pharmacies

artículo científico publicado en 2017

Time spent by Belgian hospital pharmacists on supply disruptions and drug shortages: An exploratory study

artículo científico publicado en 2017

Toward a European definition for a drug shortage: a qualitative study

artículo científico publicado en 2015

What Does Society Value About Cancer Medicines? A Discrete Choice Experiment in the Belgian Population

artículo científico publicado en 2019

Lista de obras de

Adult Refsum disease: a form of tapetoretinal dystrophy accessible to therapy

Alpha‐oxidation of 3‐methyl‐substituted fatty acids and its thiamine dependence ⬇️

Are products with an orphan designation for oncology indications different from products for other rare indications? A retrospective analysis of European orphan designations granted between 2002-2012

Breakdown of 2-hydroxylated straight chain fatty acids via peroxisomal 2-hydroxyphytanoyl-CoA lyase: a revised pathway for the alpha-oxidation of straight chain fatty acids

Call for a dedicated European legal framework for bacteriophage therapy.

Causes of drug shortages in the legal pharmaceutical framework

Clinical, Economic and Policy Implications of Drug Shortages in the European Union.

Development and implementation of "Check of Medication Appropriateness" (CMA): advanced pharmacotherapy-related clinical rules to support medication surveillance

Drug shortages in European countries: a trade-off between market attractiveness and cost containment?

Evaluation of drotrecogin alpha use in a Belgian university hospital

Financial based agreements and performance based agreements: the Belgian experience.

Further studies on the substrate spectrum of phytanoyl-CoA hydroxylase: implications for Refsum disease?

High-risk medication in community care: a scoping review

Industry Perspectives on Market Access of Innovative Drugs: The Relevance for Oncology Drugs

Insights into European drug shortages: a survey of hospital pharmacists

It is time to revise the international Good Clinical Practices guidelines: recommendations from non-commercial North-South collaborative trials

Managed Entry Agreements for Oncology Drugs: Lessons from the European Experience to Inform the Future

Market access of cancer drugs in European countries: improving resource allocation

Meropenem -valproic acid interaction in patients with cefepime-associated status epilepticus.

Optimizing the European regulatory framework for sustainable bacteriophage therapy in human medicine

Osteoporosis after combined use of a neuroleptic and antidepressants

Paving a regulatory pathway for phage therapy. Europe should muster the resources to financially, technically and legally support the introduction of phage therapy.

Predictors for reimbursement of oncology drugs in Belgium between 2002 and 2013.

Presence of thiamine pyrophosphate in mammalian peroxisomes

Role of thiamine pyrophosphate in oligomerisation, functioning and import of peroxisomal 2-hydroxyacyl-CoA lyase

Sharing of Clinical Trial Data and Samples: The Cancer Patient Perspective

Sponsorship in non-commercial clinical trials: definitions, challenges and the role of Good Clinical Practices guidelines

Tamoxifen metabolism and efficacy in breast cancer- a prospective multicentre trial

The necessity for a European definition of drug shortages

Thiamine pyrophosphate: an essential cofactor in the mammalian metabolism of 3-methyl-branched fatty acids--implications for thiamine deficiencies?

Time Investment in Drug Supply Problems by Flemish Community Pharmacies

Time spent by Belgian hospital pharmacists on supply disruptions and drug shortages: An exploratory study

Toward a European definition for a drug shortage: a qualitative study

What Does Society Value About Cancer Medicines? A Discrete Choice Experiment in the Belgian Population